Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Large Is the Nucleic Acid Therapeutics Market Expected to Be in 2029?
In recent times, there has been a noticeable escalation in the size of the nucleic acid therapeutics market. The market is projected to expand from $6.01 billion in 2024 to $6.94 billion in 2025, with a compound annual growth rate (CAGR) of 15.6%. The historical expansion can be credited to the surge in the occurrence of genetic and chronic diseases, increasing efforts in genomics research and development, a heightened use of RNA-based therapeutics, significant backing from academic and government bodies, and the rising success relating to mRNA vaccine platforms.
The market size of nucleic acid therapeutics is projected to experience rapid expansion in the coming years. By 2029, it is anticipated to reach $12.24 billion with a compound annual growth rate (CAGR) of 15.2%. Factors contributing to its growth over the forecast period include increased demand for precision medicine, the broadening applications of mRNA vaccines beyond COVID-19, the emergence of next-generation delivery platforms, a burgeoning pipeline of nucleic acid-based drugs, and a surge in approvals from regulatory bodies. Key trends expected during the forecast timeline include extending mRNA platforms to cover oncology and rare diseases, incorporating Artificial Intelligence and machine learning in RNA drug discovery, devising targeted delivery systems for tissue-specific activity, launching modular and multi-target platform therapies, and advancing next-generation aptamer technologies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27368&type=smp
What Are The Contributors To Demand In The Nucleic Acid Therapeutics Market?
The growth of the nucleic acid therapeutics market is anticipated to be driven by the escalating prevalence of genetic and chronic diseases. These terms refer to the correlation between hereditary genetic factors and the risk, progression, or inception of persistent health issues like diabetes, cardiovascular diseases, cancer, and autoimmune disorders. The upswing in such diseases is majorly contributed by enhanced diagnostic technologies that detect these conditions more precisely and early. Nucleic acid therapeutics prove beneficial for these genetic and chronic diseases as they allow to regulate, repair, or silence the fundamental genetic causes, providing exact and customized treatment options. As an example, the Cystic Fibrosis Trust, a UK-based charity supporting those with cystic fibrosis, reported in October 2024 that the number of registered cystic fibrosis patients rose from 11,148 in 2022 to 11,318 in 2023, marking a 1.5% yearly increase in patient registrations. As a result, the rise in genetic and chronic diseases fuels the expansion of the nucleic acid therapeutics market.
What Segmentation Categories Are Included In The Nucleic Acid Therapeutics Market Analysis?
The nucleic acid therapeutics market covered in this report is segmented
1) By Therapy Type: Antisense Oligonucleotides (ASOs), Small Interfering RNA (siRNA), Gene Therapies, Aptamers, Other Therapy Types
2) By Therapeutic Area: Neuromuscular Disorder, Metabolic Disorders, Cardiovascular Disorders, Ophthalmological Disorders, Oncological Disorders, Other Therapeutic Areas
3) By Route Of Administration: Intravenous, Subcutaneous, Other Route Of Administrations
4) By Delivery Method: Viral Vector-Based Delivery Systems, Non-Viral Delivery Systems
5) By End-Use: Pharmaceutical Companies, Government And Academic Research Institutes, Biotech Companies
Subsegment:
1) By Antisense Oligonucleotides (ASOs): Phosphorothioate ASOs, 2’-O-Methyl ASOs, Locked Nucleic Acid (LNA) ASOs, Gapmer ASOs, Morpholino ASOs
2) By Small Interfering RNA (siRNA): Lipid Nanoparticle (LNP) Formulated siRNA, GalNAc-Conjugated siRNA, Chemically Modified siRNA, Naked siRNA
3) By Gene Therapies: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, CRISPR-Based Gene Therapy, Zinc Finger Nucleases (ZFNs), TALENs
4) By Aptamers: Ribonucleic Acid (RNA) Aptamers, Deoxyribonucleic Acid (DNA) Aptamers, Spiegelmers, Pegylated Aptamers
5) By Others Therapy Types: MicroRNA (miRNA) Therapeutics, Long Non-Coding RNA (lncRNA) Therapeutics, Ribonucleic Acid (RNA) Editing Therapies, Ribozymes
What Upcoming Trends Are Expected To Impact The Nucleic Acid Therapeutics Market Globally?
Leading firms in the nucleic acid therapeutics market are channeling their efforts towards the creation of innovative solutions, like antisense oligonucleotide therapy, which aims to target and suppress specific genes causing diseases. This provides precision treatments for genetic disorders and rare diseases. This therapeutic approach entails using short, synthetic strands of DNA or RNA to interfere with or modify the expression of particular genes implicated in diseases. For instance, Ionis Pharmaceuticals Inc., a biotech company based in the US, received approval from the U.S. Food and Drug Administration (FDA) in December 2024 for TRYNGOLZ (olezarsen), as a supplementary treatment to diet for the reduction of triglyceride levels in adults with familial chylomicronemia syndrome (FCS). FCS is a rare genetic disorder marked by a considerably high level of triglycerides (sHTG) and an increased risk of acute pancreatitis (AP). This is the first FDA-approved treatment that renders a significant and long-lasting reduction of triglyceride levels in this group of patients, in addition to a clinically significant decrease in the incidence of AP when used alongside a low-fat diet. This therapy is developed for easy self-administration, delivered through an auto-injector once a month.
Who Are The Top-Ranked Companies In The Nucleic Acid Therapeutics Market Today?
Major companies operating in the nucleic acid therapeutics market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Novartis AG, Moderna Inc., BioNTech SE, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Imugene Limited, CureVac SE, Sangamo Therapeutics Inc., Beam Therapeutics Inc., Arbutus Biopharma Corporation, Silence Therapeutics plc, Copernicus Therapeutics Inc., and Exothera S.A.
Get The Full Report Here:
https://www.thebusinessresearchcompany.com/report/nucleic-acid-therapeutics-global-market-report
How Is Nucleic Acid Therapeutics Market Adoption Varying Across Different Regions And Sectors?
North America was the largest region in the nucleic acid therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nucleic acid therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=27368&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model